Free Trial
NASDAQ:ARAY

Accuray (ARAY) Stock Price, News & Analysis

Accuray logo
$1.52 +0.03 (+1.68%)
As of 05/9/2025 03:58 PM Eastern

About Accuray Stock (NASDAQ:ARAY)

Key Stats

Today's Range
$1.48
$1.54
50-Day Range
$1.31
$1.91
52-Week Range
$1.28
$2.95
Volume
572,130 shs
Average Volume
709,984 shs
Market Capitalization
$155.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Accuray Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

ARAY MarketRank™: 

Accuray scored higher than 63% of companies evaluated by MarketBeat, and ranked 398th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Accuray.

  • Earnings Growth

    Earnings for Accuray are expected to grow by 1,100.00% in the coming year, from $0.01 to $0.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Accuray is -30.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Accuray is -30.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Accuray has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.01% of the float of Accuray has been sold short.
  • Short Interest Ratio / Days to Cover

    Accuray has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Accuray has recently decreased by 8.35%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Accuray does not currently pay a dividend.

  • Dividend Growth

    Accuray does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.01% of the float of Accuray has been sold short.
  • Short Interest Ratio / Days to Cover

    Accuray has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Accuray has recently decreased by 8.35%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Accuray has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Accuray this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for ARAY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Accuray to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Accuray insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.23% of the stock of Accuray is held by insiders.

  • Percentage Held by Institutions

    64.08% of the stock of Accuray is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Accuray's insider trading history.
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Stock News Headlines

100-year-old investment secret predicts what?!
Did you know? There's a strange investment secret discovered just before the Great Depression … That accurately called all the major financial events in recent history …
Accuray (NASDAQ:ARAY) Stock Rating Lowered by StockNews.com
See More Headlines

ARAY Stock Analysis - Frequently Asked Questions

Accuray's stock was trading at $1.98 on January 1st, 2025. Since then, ARAY shares have decreased by 23.5% and is now trading at $1.5150.
View the best growth stocks for 2025 here
.

Accuray Incorporated (NASDAQ:ARAY) issued its earnings results on Wednesday, April, 30th. The medical equipment provider reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. The medical equipment provider earned $113.24 million during the quarter, compared to analyst estimates of $101.53 million. Accuray had a negative net margin of 0.96% and a negative trailing twelve-month return on equity of 9.75%.
Read the conference call transcript
.

The following companies are subsidiaries of Accuray: Morphormics Inc., TomoTherapy Incorporated, Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, and more.

Top institutional investors of Accuray include Heartland Advisors Inc. (4.16%), Foundry Partners LLC (1.75%), Acuitas Investments LLC (1.38%) and North Star Investment Management Corp. (1.03%). Insiders that own company stock include Suzanne C Winter, Sandeep Chalke, Joseph E Whitters, Jesse Chew, Michael Hoge, Ali Pervaiz, Patrick Spine and Gina Corradetti.
View institutional ownership trends
.

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accuray investors own include Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (vygr), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
4/30/2025
Today
5/09/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ARAY
Employees
1,040
Year Founded
1990

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
151.50
P/E Growth
N/A
Net Income
$-15,550,000.00
Pretax Margin
-0.47%

Debt

Sales & Book Value

Annual Sales
$465.25 million
Price / Cash Flow
N/A
Book Value
$0.45 per share
Price / Book
3.37

Miscellaneous

Free Float
98,481,000
Market Cap
$155.79 million
Optionable
Optionable
Beta
1.30

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ARAY) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners